ObjectiveShort-acting bronchodilators for asthma and chronic obstructive pulmonary disease (COPD) exacerbations are commonly delivered by nebulizers although administration using metered dose inhaler with space chamber (MDI spacer) has been shown to be equally efficacious. There are few studies examining patients' and healthcare providers' attitudes on the 2 administration methods in adults. This study explores patients' and healthcare providers' attitudes on the use of nebulizer versus MDI spacer for acute asthma and COPD exacerbations in adults.MethodsPatients admitted for asthma or COPD exacerbations, doctors and nurses in a university-affiliated hospital were surveyed from 1 April 2021 to 30 Sept 2021 regarding their views on the effectiveness, ease of use, preparation and administration, side effects, and infection risk of the 2 administration methods.ResultsNinety-nine patients, 103 doctors and 650 nurses completed the survey. 60.6% of patients perceived nebulizer to be more effective. Patients who found nebulizer more comfortable were more likely to prefer nebulizer (OR 43.97, p = 0.01), while those who associated it with a greater infection risk were less likely to prefer nebulizer (OR 0.15, p = 0.03). 49.5% of doctors and 49.1% of nurses perceived nebulizer to be more effective, compared to 10.7% and 34.5%, respectively, for MDI spacer. Effectiveness and patient comfort influenced doctors' and nurses' preference for nebulizer while ease of preparation and administration influenced nurses' preference only.ConclusionsPatients and healthcare providers perceived nebulizer to be more effective. Factors unique to each group influenced their preference for nebulizer.
Nebulizer versus metered dose inhaler with space chamber (MDI spacer) for acute asthma and chronic obstructive pulmonary disease (COPD) exacerbation: attitudes of patients and healthcare providers in the COVID-19 era.